Hongxing Corp.(001209)
Search documents
洪兴股份:董秘刘根祥和副总程胜祥已分别减持0.0249%和0.0368%
Xin Lang Cai Jing· 2026-02-25 11:00
洪兴股份公告,公司董事会秘书兼财务总监刘根祥于2026年2月12日至2026年2月24日通过集中竞价累计 减持31960股,占扣除回购股份后总股本0.0249%;副总经理程胜祥同期通过集中竞价累计减持47348 股,占0.0368%。两人均按2026年1月22日披露的计划实施减持,减持股份来源均为公司首次公开发行 前取得的股份。本次减持计划现已完成。 ...
洪兴股份2026年2月25日涨停分析:公司治理优化+产能提升预期+服饰行业经验
Xin Lang Cai Jing· 2026-02-25 05:31
Core Viewpoint - Hongxing Co., Ltd. (SZ001209) experienced a trading halt with a price of 26.87 yuan, marking a 9.99% increase, and a total market capitalization of 3.534 billion yuan [1] Group 1: Company Governance and Management - Recent announcements indicate that multiple governance system revisions have been approved, ensuring compliance and enhancing market confidence in the company [2] - The retention of the former board secretary and financial director ensures continuity, while the new board member brings 20 years of experience in the apparel industry, which is beneficial for business development [2] Group 2: Capacity and Profitability Outlook - The company is transitioning construction projects to fixed assets, which may lead to future capacity increases or operational efficiency improvements [2] - Despite a significant expected decline in net profit for 2025, the company is projected to achieve a profit of 17 to 21 million yuan, indicating a foundation and potential for recovery [2] Group 3: Industry Trends - The apparel and home textile sector has shown recent activity, with some stocks in the sector experiencing gains, potentially creating a sector-wide momentum effect [2] - Technical analysis suggests that Hongxing Co., Ltd. may have broken through a key resistance level, attracting more investor attention and contributing to the stock's trading halt [2]
广东洪兴实业股份有限公司关于股票交易异常波动的公告
Xin Lang Cai Jing· 2026-02-08 18:30
Core Viewpoint - Guangdong Hongxing Industrial Co., Ltd. experienced a significant stock price fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days in early February 2026, which is classified as abnormal trading activity [2]. Group 1: Stock Trading Abnormality - The company's stock price rose significantly on February 4, 5, and 6, 2026, with a cumulative price deviation exceeding 20% [2]. - The company has conducted an internal review regarding the stock's abnormal trading and confirmed that there are no undisclosed significant matters affecting the stock price [3][5]. Group 2: Company Operations and Information Disclosure - The company has verified that there are no recent media reports that could have significantly impacted the stock price [4]. - The company's operational situation remains normal, and there have been no significant changes in the internal or external business environment [5]. - The company and its controlling shareholders did not engage in any stock trading during the period of abnormal price fluctuation [6]. Group 3: Disclosure Compliance - The board of directors confirmed that there are no undisclosed matters that should have been disclosed according to the Shenzhen Stock Exchange regulations [7]. - The company previously announced a performance forecast for 2025, estimating a net profit of 17 million to 21 million yuan, representing a decline of 73.84% to 78.82% compared to the previous year [8].
洪兴股份:股票交易异常波动,连续三日涨幅偏离值超20%,核查无应披露未披露事项
Jin Rong Jie· 2026-02-08 08:04
Core Viewpoint - Hongxing Co., Ltd. announced that its stock price experienced a cumulative deviation of over 20% during three consecutive trading days from February 4 to February 6, 2026, while confirming that there are no undisclosed significant matters affecting the stock price [1] Group 1: Stock Performance - The company's stock price increased significantly, with a cumulative price deviation exceeding 20% over three trading days [1] - The company confirmed that there were no recent media reports that could have influenced the stock price [1] Group 2: Financial Performance - The 2025 annual performance forecast indicates that the net profit attributable to shareholders is expected to be between 17 million and 21 million, representing a decline of 73.84% to 78.82% compared to the same period last year [1] - As of the announcement date, there are no corrections needed for the profit forecast [1] Group 3: Corporate Governance - The controlling shareholders and actual controllers did not buy or sell company stock during the period of abnormal stock fluctuations [1] - The company stated that its recent operational situation is normal and there are no significant undisclosed matters [1]
洪兴股份(001209) - 关于股票交易异常波动的公告
2026-02-08 07:45
证券代码:001209 证券简称:洪兴股份 公告编号:2026-004 广东洪兴实业股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整,没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 广东洪兴实业股份有限公司(以下简称"公司"或"本公司")股票价格于 2026 年 2 月 4 日、2026 年 2 月 5 日、2026 年 2 月 6 日连续三个交易日收盘价格 涨幅偏离值累计超过 20%,根据《深圳证券交易所交易规则》的有关规定,属于 股票异常波动的情况。 3.近期公司经营情况正常,内外部经营环境未发生重大变化。 4.经核查,公司、控股股东和实际控制人不存在关于本公司的应披露而未披 露或处于筹划阶段的重大事项。 5.经查询,公司控股股东及实际控制人在本公司股票异常波动期间未买卖公 司股票。 三、是否存在应披露而未披露信息的说明 本公司董事会确认,目前没有任何根据《深圳证券交易所股票上市规则》等有 关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、协议等; 董事会也未获悉本公司有根据《深圳证券交易所股票上市规则》等有关规定应予 ...
雪祺电气:已建立外汇套期保值制度,开展远期结售汇等衍生品业务应对汇率风险
2 1 Shi Ji Jing Ji Bao Dao· 2026-02-05 09:36
Group 1 - The core viewpoint of the article is that Xueqi Electric is implementing measures to mitigate foreign exchange risks and enhance financial stability through a structured foreign exchange hedging management system [1] - The company is engaging in various foreign exchange derivative activities, including forward foreign exchange settlements, structured forwards, foreign exchange swaps, and foreign exchange options [1] - Xueqi Electric plans to continuously monitor foreign exchange market trends and proactively adopt targeted measures to minimize the adverse impact of exchange rate fluctuations on its performance [1]
洪兴股份:2025年度业绩预告
Zheng Quan Ri Bao· 2026-01-29 13:29
Group 1 - The core point of the article is that Hongxing Co., Ltd. has announced an expected net profit for 2025, projected to be between 17 million yuan and 21 million yuan [2] Group 2 - The announcement was made on January 29, indicating the company's forward-looking financial outlook [2] - The profit range suggests a cautious optimism regarding the company's performance in the upcoming years [2]
1月29日晚间重要公告一览
Xi Niu Cai Jing· 2026-01-29 10:13
Earnings Forecasts - Shengyi Electronics expects a net profit of 1.431 billion to 1.513 billion yuan in 2025, an increase of 331.03% to 355.88% year-on-year [1] - Tigermed anticipates a net profit of 830 million to 1.23 billion yuan in 2025, representing a growth of 105% to 204% year-on-year [2] - Shunbo Alloy forecasts a net profit of 210 million to 270 million yuan in 2025, with an increase of 222.96% to 315.23% year-on-year [3] - Jinkong Electric expects a net profit of 155 million to 195 million yuan in 2025, reflecting a growth of 383.21% to 507.9% year-on-year [9] - Baiao Saitu anticipates a net profit of 162 million to 182 million yuan in 2025, with a year-on-year increase of 384.26% to 443.88% [18] - Panjiang Co. expects a net profit of 318 million to 380 million yuan in 2025, representing a growth of 205.30% to 264.83% year-on-year [38] Loss Forecasts - Liaoning Energy predicts a net loss of 273 million to 410 million yuan in 2025, compared to a profit of 202 million yuan in the previous year [5] - Anbotong anticipates a net loss of 114 million to 165 million yuan in 2025, with a revenue decrease of 19.65% to 27.25% [7] - Wantai Bio forecasts a net loss of 330 million to 410 million yuan in 2025, compared to a profit of 106 million yuan in the previous year [12] - Xingyun Co. expects a net loss of 155 million to 230 million yuan in 2025, compared to a loss of 82.44 million yuan in the previous year [20] - Huaxing Co. anticipates a net loss of 800 million to 1.2 billion yuan in 2025, with a reduction in loss compared to 1.67 billion yuan in the previous year [46] New Product Approvals - Hengrui Medicine received acceptance for a new indication application for its innovative drug, combining Carrelizumab and Apatinib for treating unresectable liver cancer [4] - Tianen Kang's subsidiary received a drug registration acceptance notice for Lidocaine and Prilocaine aerosol [31] - Lisheng Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs [40] Share Buyback Plans - Hengyuan Coal Power plans to repurchase shares with a total amount not less than 200 million yuan and not exceeding 250 million yuan [13] Contract Wins - China Communication Signal Co. won contracts totaling approximately 5.26 billion yuan for 21 important projects in the railway and urban rail transit markets [37]
洪兴股份(001209.SZ):预计2025年净利润同比下降73.84%-78.82%
Ge Long Hui A P P· 2026-01-29 08:39
Core Viewpoint - Hongxing Co., Ltd. (001209.SZ) expects a significant decline in net profit for 2025, projecting a range of 17 million to 21 million yuan, which represents a decrease of 73.84% to 78.82% compared to the same period last year [1] Financial Performance - The net profit attributable to shareholders is forecasted to be between 17 million and 21 million yuan, indicating a substantial year-on-year decline [1] - The net profit after deducting non-recurring gains and losses is estimated to be between 8.5 million and 12.5 million yuan, reflecting a decrease of 69.06% to 78.96% year-on-year [1] Industry Context - The industry is experiencing intense competition, which has led to a decline in the company's overall sales gross margin [1] - The performance of offline channel business has not met expectations, contributing to the financial outlook [1] - The company has completed construction projects that are now being depreciated, impacting financial results [1]
洪兴股份:2025年全年净利润同比预减73.84%—78.82%
2 1 Shi Ji Jing Ji Bao Dao· 2026-01-29 08:22
Core Viewpoint - Hongxing Co., Ltd. is expected to report a significant decline in net profit for the year 2025, with projections indicating a decrease of 73.84% to 78.82% compared to the previous year [1] Financial Performance - The estimated net profit attributable to shareholders for 2025 is projected to be between 17 million and 21 million yuan [1] - The estimated net profit excluding non-recurring items is projected to be between 8.5 million and 12.5 million yuan, reflecting a year-on-year decrease of 69.06% to 78.96% [1] Reasons for Performance Change - The absence of insurance compensation received in the previous year amounting to 46.5 million yuan, classified as non-recurring income, is a primary factor for the profit decline [1] - Increased industry competition has led to a decrease in the company's overall sales gross margin and underperformance in offline channel business [1] - The completion of construction projects has resulted in the commencement of depreciation charges [1]